Risk of Bacterial Resistance in Systemic Antibiotic Use for Acne

  01 April 2022

Antibiotics for acne continue to come with ambiguities concerning long-term use and antibiotic resistance. In a presentation at the recent American Academy of Dermatology (AAD) Annual Meeting, held March 25 to 29, in Boston, Massachusetts, Diane M. Thiboutot, MD, highlighted data on these issues and potential alternatives to some frequently used options.1

Thiboutot is a professor of dermatology at the Pennsylvania State University College of Medicine, in Hershey.

Systemic antibiotics are recommended for moderate to severe acne management and forms of inflammatory acne resistant to topical alternatives, she said. Of the systemic antibiotic options, she noted that doxycycline and minocycline are more effective than tetracycline, however neither doxycycline nor minocycline is superior then the other.

Oral erythromycin and azithromycin should be limited to patients unable to use tetracyclines, like those who are pregnant or children under 8 years old. Additionally, erythromycin should be restricted as it holds an increased risk of bacterial resistance, according to Thiboutot.

Further reading: Dermatology Times
Author(s): Katie Hobbins
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed